Brentuximab Vedotin og Nivolumab med eller uden Ipilimumab til behandling af patienter med recidiverende eller refraktær Hodgkin-lymfom
Et fase I-studie med en ekspansionskohorte/randomiseret fase II-undersøgelse af kombinationer af Ipilimumab, Nivolumab og Brentuximab Vedotin hos patienter med recidiverende/refraktær Hodgkin-lymfom
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to brentuximab vedotin, ipilimumab, and nivolumab. (Phase II; adult cohort [aged >= 18 years]) III. To characterize the safety and toxicity of treatment combination in the pediatric population. (Phase II; pediatric cohort [aged 12-17 years])
SECONDARY OBJECTIVES:
I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response rate (ORR), for the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the duration of remission (DOR) to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase I) III. To evaluate the progression-free survival (PFS) and the overall survival (OS) in patients receiving the combination of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) IV. To evaluate the ORR, PR, and stable disease (SD) rate for the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) V. To evaluate the DOR to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase II) VI. To evaluate the 5 year PFS and OS in patients receiving the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) VII. To further evaluate the safety and characterize the toxicity for the combinations of brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)
CORRELATIVE STUDY OBJECTIVES:
I. To evaluate the ability of these combinations to alter tumor specific T cell immunity. (Phase I) II. To evaluate the effects of these combinations on systemic immunity. (Phase I) III. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood as a potential immune signature of treatment response to therapy with these combinations for patients with relapsed/refractory Hodgkin lymphoma (HL). (Phase I) IV. To evaluate using gene expression profiling (GEP) a signature of response to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase I) V. To evaluate the ability of these combinations to alter tumor specific T cell immunity, and circulating T cell phenotypes, in patients as a function of treatment response at multiple timepoints during therapy. (Phase II) VI. To evaluate peripheral blood cytokine profiles in responding and resistant patients at multiple timepoints during therapy. (Phase II) VII. To evaluate using GEP a signature of response versus (vs.) resistance to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase II) VIII. To evaluate the influence of human gut microbiome dysbiosis on HL lymphomagenesis and the systemic immune response. (Phase II)
IMAGING CORRELATIVE STUDY OBJECTIVES:
I. To evaluate atypical response patterns with currently available response evaluation criteria. (Phase II) II. To correlate response evaluated using currently available response evaluation criteria with duration of response (PFS, event free survival [EFS], failure free survival [FFS]). (Phase II) III. To evaluate response patterns in different immunotherapy treatment schemes and correlate with historical data using chemotherapy. (Phase II) IV. To correlate imaging changes in all treatment schemes quantitatively with PFS. (Phase II)
EXPLORATORY OBJECTIVES:
I. Evaluate outcomes (CR, PFS) between patients with/without prior transplants. (Phase II) II. Evaluate outcomes (PFS, OS) between the patients who stay on treatment and do not go to transplant in both arms (the post auto and the few others who don't want transplant) vs the patients who go off for transplant. (Phase II) III. Evaluate outcomes (CR, PFS) in pediatric population (age 12 to < 18 years of age) vs. adult population. (Phase II)
OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin, ipilimumab, and nivolumab followed by a phase II study.
PHASE I: Patients are assigned into 1 of 3 arms.
ARM I: Patients receive brentuximab vedotin intravenously (IV) over 90 minutes on day 1 of cycles 1-16 and ipilimumab IV over 30 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and nivolumab IV over 90 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.
All patients also undergo computed tomography (CT) or positron emission tomography (PET) scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
After completion of phase I study treatment, patients are followed up every 3 months for 1 year, then every 6 months for 2 years. After completion of phase II study treatment, patients are followed up for 10 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama at Birmingham Cancer Center
-
Birmingham, Alabama, Forenede Stater, 35233
- Children's Hospital of Alabama
-
-
Alaska
-
Anchorage, Alaska, Forenede Stater, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Forenede Stater, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Forenede Stater, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Forenede Stater, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Forenede Stater, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Forenede Stater, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Forenede Stater, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Forenede Stater, 99504
- Anchorage Radiation Therapy Center
-
Fairbanks, Alaska, Forenede Stater, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Kingman, Arizona, Forenede Stater, 86401
- Kingman Regional Medical Center
-
Phoenix, Arizona, Forenede Stater, 85004
- Cancer Center at Saint Joseph's
-
-
Arkansas
-
Fort Smith, Arkansas, Forenede Stater, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Forenede Stater, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Antioch, California, Forenede Stater, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Arroyo Grande, California, Forenede Stater, 93420
- PCR Oncology
-
Arroyo Grande, California, Forenede Stater, 93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Burbank, California, Forenede Stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Dublin, California, Forenede Stater, 94568
- Kaiser Permanente Dublin
-
Fremont, California, Forenede Stater, 94538
- Kaiser Permanente-Fremont
-
Fresno, California, Forenede Stater, 93720
- Kaiser Permanente-Fresno
-
Fresno, California, Forenede Stater, 93720
- Fresno Cancer Center
-
Modesto, California, Forenede Stater, 95356
- Kaiser Permanente-Modesto
-
Oakland, California, Forenede Stater, 94611
- Kaiser Permanente-Oakland
-
Oakland, California, Forenede Stater, 94611
- Kaiser Permanente Oakland-Broadway
-
Orange, California, Forenede Stater, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Forenede Stater, 94304
- Stanford Cancer Institute Palo Alto
-
Rancho Cordova, California, Forenede Stater, 95670
- Kaiser Permanente-Rancho Cordova Cancer Center
-
Redwood City, California, Forenede Stater, 94063
- Kaiser Permanente-Redwood City
-
Richmond, California, Forenede Stater, 94801
- Kaiser Permanente-Richmond
-
Rohnert Park, California, Forenede Stater, 94928
- Rohnert Park Cancer Center
-
Roseville, California, Forenede Stater, 95678
- The Permanente Medical Group-Roseville Radiation Oncology
-
Roseville, California, Forenede Stater, 95661
- Kaiser Permanente-Roseville
-
Sacramento, California, Forenede Stater, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Forenede Stater, 95823
- Kaiser Permanente-South Sacramento
-
Sacramento, California, Forenede Stater, 95823
- South Sacramento Cancer Center
-
Sacramento, California, Forenede Stater, 95825
- Kaiser Permanente Sacramento Medical Center
-
San Francisco, California, Forenede Stater, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Forenede Stater, 94158
- UCSF Medical Center-Mission Bay
-
San Jose, California, Forenede Stater, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Forenede Stater, 94577
- Kaiser Permanente San Leandro
-
San Luis Obispo, California, Forenede Stater, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
San Rafael, California, Forenede Stater, 94903
- Kaiser San Rafael-Gallinas
-
San Rafael, California, Forenede Stater, 94903
- Kaiser Permanente-San Rafael
-
Santa Clara, California, Forenede Stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Maria, California, Forenede Stater, 93444
- Mission Hope Medical Oncology - Santa Maria
-
Santa Rosa, California, Forenede Stater, 95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco, California, Forenede Stater, 94080
- Kaiser Permanente Cancer Treatment Center
-
South San Francisco, California, Forenede Stater, 94080
- Kaiser Permanente-South San Francisco
-
Stockton, California, Forenede Stater, 95210
- Kaiser Permanente-Stockton
-
Vacaville, California, Forenede Stater, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Forenede Stater, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Forenede Stater, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Forenede Stater, 80012
- The Medical Center of Aurora
-
Boulder, Colorado, Forenede Stater, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Forenede Stater, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, Forenede Stater, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Denver, Colorado, Forenede Stater, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Forenede Stater, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Denver, Colorado, Forenede Stater, 80220
- Rose Medical Center
-
Denver, Colorado, Forenede Stater, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Forenede Stater, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Forenede Stater, 80204
- Denver Health Medical Center
-
Denver, Colorado, Forenede Stater, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, Forenede Stater, 80204
- Cancer Center of Colorado at Sloan's Lake
-
Denver, Colorado, Forenede Stater, 80209
- The Women's Imaging Center
-
Denver, Colorado, Forenede Stater, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Forenede Stater, 80220
- Western Surgical Care
-
Denver, Colorado, Forenede Stater, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Forenede Stater, 80210
- AdventHealth Porter
-
Durango, Colorado, Forenede Stater, 81301
- Mercy Medical Center
-
Durango, Colorado, Forenede Stater, 81301
- CommonSpirit Cancer Center Mercy
-
Englewood, Colorado, Forenede Stater, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Forenede Stater, 80113
- Swedish Medical Center
-
Englewood, Colorado, Forenede Stater, 80113
- Rocky Mountain Cancer Centers - Swedish
-
Golden, Colorado, Forenede Stater, 80401
- Mountain Blue Cancer Care Center
-
Golden, Colorado, Forenede Stater, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Forenede Stater, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley, Colorado, Forenede Stater, 80631
- Banner North Colorado Medical Center
-
Lafayette, Colorado, Forenede Stater, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Lakewood, Colorado, Forenede Stater, 80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood, Colorado, Forenede Stater, 80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton, Colorado, Forenede Stater, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Littleton, Colorado, Forenede Stater, 80122
- AdventHealth Littleton
-
Lone Tree, Colorado, Forenede Stater, 80124
- Sky Ridge Medical Center
-
Lone Tree, Colorado, Forenede Stater, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont, Colorado, Forenede Stater, 80501
- Longmont United Hospital
-
Longmont, Colorado, Forenede Stater, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Loveland, Colorado, Forenede Stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, Forenede Stater, 80138
- Rocky Mountain Cancer Centers-Parker
-
Parker, Colorado, Forenede Stater, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Forenede Stater, 81008
- Rocky Mountain Cancer Centers - Pueblo
-
Thornton, Colorado, Forenede Stater, 80260
- Rocky Mountain Cancer Centers-Thornton
-
Thornton, Colorado, Forenede Stater, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, Forenede Stater, 80401
- Intermountain Health Lutheran Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Children's National Medical Center
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Fort Myers, Florida, Forenede Stater, 33908
- Golisano Children's Hospital of Southwest Florida
-
St. Petersburg, Florida, Forenede Stater, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Forenede Stater, 33606
- Tampa General Hospital
-
Tampa, Florida, Forenede Stater, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Forenede Stater, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forenede Stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forenede Stater, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Forenede Stater, 83617
- Walter Knox Memorial Hospital
-
Fruitland, Idaho, Forenede Stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forenede Stater, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Forenede Stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forenede Stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forenede Stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Forenede Stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Forenede Stater, 62002
- OSF Saint Anthony's Health Center
-
Aurora, Illinois, Forenede Stater, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Forenede Stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forenede Stater, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Forenede Stater, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Forenede Stater, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Forenede Stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forenede Stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60612
- University of Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Forenede Stater, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forenede Stater, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Forenede Stater, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Forenede Stater, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Forenede Stater, 61401
- Illinois CancerCare-Galesburg
-
Joliet, Illinois, Forenede Stater, 60435
- Duly Health and Care Joliet
-
Kewanee, Illinois, Forenede Stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forenede Stater, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Forenede Stater, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Forenede Stater, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Forenede Stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Forenede Stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forenede Stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forenede Stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forenede Stater, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Forenede Stater, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Forenede Stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forenede Stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forenede Stater, 62781
- Springfield Memorial Hospital
-
Swansea, Illinois, Forenede Stater, 62226
- Southwest Illinois Health Services LLP
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
Urbana, Illinois, Forenede Stater, 61801
- The Carle Foundation Hospital
-
Washington, Illinois, Forenede Stater, 61571
- Illinois CancerCare - Washington
-
Yorkville, Illinois, Forenede Stater, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Evansville, Indiana, Forenede Stater, 47713
- Deaconess Clinic Downtown
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Newburgh, Indiana, Forenede Stater, 47630
- Chancellor Center for Oncology
-
-
Iowa
-
Clive, Iowa, Forenede Stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Forenede Stater, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Forenede Stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
West Des Moines, Iowa, Forenede Stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City, Kansas, Forenede Stater, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Forenede Stater, 67530
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Bardstown, Kentucky, Forenede Stater, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Forenede Stater, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Forenede Stater, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Forenede Stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
London, Kentucky, Forenede Stater, 40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville, Kentucky, Forenede Stater, 40202
- Jewish Hospital
-
Louisville, Kentucky, Forenede Stater, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Forenede Stater, 40215
- Saints Mary and Elizabeth Hospital
-
Paducah, Kentucky, Forenede Stater, 42003
- Mercy Health - Paducah Cancer Center
-
Shepherdsville, Kentucky, Forenede Stater, 40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Our Lady of the Lake Physician Group
-
Covington, Louisiana, Forenede Stater, 70433
- Northshore Oncology Associates-Covington
-
Houma, Louisiana, Forenede Stater, 70360
- Terrebonne General Medical Center
-
Houma, Louisiana, Forenede Stater, 70360
- Oncology Center of The South Incorporated
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Forenede Stater, 21229
- Saint Agnes Hospital
-
Bethesda, Maryland, Forenede Stater, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Tufts Medical Center
-
-
Michigan
-
Port Huron, Michigan, Forenede Stater, 48060
- Lake Huron Medical Center
-
Port Huron, Michigan, Forenede Stater, 48060
- Huron Medical Center PC
-
-
Minnesota
-
Aitkin, Minnesota, Forenede Stater, 56431
- Riverwood Healthcare Center
-
Brainerd, Minnesota, Forenede Stater, 56401
- Essentia Health Saint Joseph's Medical Center
-
Deer River, Minnesota, Forenede Stater, 56636
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Forenede Stater, 56501
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Forenede Stater, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Forenede Stater, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Forenede Stater, 55805
- Miller-Dwan Hospital
-
Fergus Falls, Minnesota, Forenede Stater, 56537
- Lake Region Healthcare Corporation-Cancer Care
-
Fosston, Minnesota, Forenede Stater, 56542
- Essentia Health - Fosston
-
Hibbing, Minnesota, Forenede Stater, 55746
- Essentia Health Hibbing Clinic
-
Park Rapids, Minnesota, Forenede Stater, 56470
- Essentia Health - Park Rapids
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, Forenede Stater, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Forenede Stater, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Ballwin, Missouri, Forenede Stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Forenede Stater, 65613
- Central Care Cancer Center - Bolivar
-
Bonne Terre, Missouri, Forenede Stater, 63628
- Parkland Health Center-Bonne Terre
-
Branson, Missouri, Forenede Stater, 65616
- Cox Cancer Center Branson
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Mercy Cancer Center - Cape Girardeau
-
Chesterfield, Missouri, Forenede Stater, 63017
- Saint Luke's Hospital
-
City of Saint Peters, Missouri, Forenede Stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Forenede Stater, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Forenede Stater, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Forenede Stater, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Forenede Stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forenede Stater, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Forenede Stater, 64108
- Children's Mercy Hospitals and Clinics
-
Rolla, Missouri, Forenede Stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forenede Stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Forenede Stater, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Forenede Stater, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Forenede Stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Forenede Stater, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Forenede Stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forenede Stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forenede Stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forenede Stater, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Forenede Stater, 63080
- Missouri Baptist Sullivan Hospital
-
Washington, Missouri, Forenede Stater, 63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda, Montana, Forenede Stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forenede Stater, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Forenede Stater, 59101
- Saint Vincent Healthcare
-
Billings, Montana, Forenede Stater, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Forenede Stater, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Forenede Stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forenede Stater, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Forenede Stater, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Forenede Stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forenede Stater, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Forenede Stater, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Forenede Stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Forenede Stater, 68847
- CHI Health Good Samaritan
-
Kearney, Nebraska, Forenede Stater, 68845
- Fred and Pamela Buffett Cancer Center - Kearney
-
Lincoln, Nebraska, Forenede Stater, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Forenede Stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Forenede Stater, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Forenede Stater, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Forenede Stater, 68122
- Hematology and Oncology Consultants PC
-
Papillion, Nebraska, Forenede Stater, 68046
- Midlands Community Hospital
-
-
Nevada
-
Carson City, Nevada, Forenede Stater, 89703
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Forenede Stater, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Forenede Stater, 89052
- Cancer and Blood Specialists-Henderson
-
Henderson, Nevada, Forenede Stater, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Forenede Stater, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, Forenede Stater, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Forenede Stater, 89074
- Las Vegas Urology - Green Valley
-
Henderson, Nevada, Forenede Stater, 89074
- Las Vegas Urology - Pebble
-
Henderson, Nevada, Forenede Stater, 89074
- Urology Specialists of Nevada - Green Valley
-
Henderson, Nevada, Forenede Stater, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, Forenede Stater, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Forenede Stater, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Forenede Stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forenede Stater, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Forenede Stater, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Forenede Stater, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Forenede Stater, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Forenede Stater, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Forenede Stater, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Forenede Stater, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Forenede Stater, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Forenede Stater, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Forenede Stater, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Forenede Stater, 89106
- Cancer and Blood Specialists-Shadow
-
Las Vegas, Nevada, Forenede Stater, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, Forenede Stater, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, Forenede Stater, 89128
- Cancer and Blood Specialists-Tenaya
-
Las Vegas, Nevada, Forenede Stater, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, Forenede Stater, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Forenede Stater, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, Forenede Stater, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Forenede Stater, 89074
- Las Vegas Urology - Pecos
-
Las Vegas, Nevada, Forenede Stater, 89102
- Desert West Surgery
-
Las Vegas, Nevada, Forenede Stater, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Forenede Stater, 89106
- Urology Specialists of Nevada - Central
-
Las Vegas, Nevada, Forenede Stater, 89113
- Las Vegas Prostate Cancer Center
-
Las Vegas, Nevada, Forenede Stater, 89113
- Las Vegas Urology - Sunset
-
Las Vegas, Nevada, Forenede Stater, 89128
- Las Vegas Urology - Cathedral Rock
-
Las Vegas, Nevada, Forenede Stater, 89128
- Las Vegas Urology - Smoke Ranch
-
Las Vegas, Nevada, Forenede Stater, 89128
- Urology Specialists of Nevada - Northwest
-
Las Vegas, Nevada, Forenede Stater, 89169
- University Cancer Center
-
Las Vegas, Nevada, Forenede Stater, 89113
- Urology Specialists of Nevada - Southwest
-
Las Vegas, Nevada, Forenede Stater, 89128
- Oncology Las Vegas - Tenaya
-
Las Vegas, Nevada, Forenede Stater, 89183
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Forenede Stater, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Forenede Stater, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Forenede Stater, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Forenede Stater, 89509
- Radiation Oncology Associates
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Hackensack University Medical Center
-
Lakewood, New Jersey, Forenede Stater, 08701
- Monmouth Medical Center Southern Campus
-
Long Branch, New Jersey, Forenede Stater, 07740
- Monmouth Medical Center
-
Morristown, New Jersey, Forenede Stater, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rutgers Cancer Institute of New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Albany Medical Center
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10029
- Mount Sinai Hospital
-
New York, New York, Forenede Stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Forenede Stater, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Forenede Stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Stony Brook, New York, Forenede Stater, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Forenede Stater, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Forenede Stater, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Clinton, North Carolina, Forenede Stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Forenede Stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Goldsboro, North Carolina, Forenede Stater, 27534
- Wayne Memorial Hospital
-
Jacksonville, North Carolina, Forenede Stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Jacksonville, North Carolina, Forenede Stater, 28546
- Onslow Memorial Hospital
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58103
- Essentia Health Cancer Center-South University Clinic
-
Jamestown, North Dakota, Forenede Stater, 58401
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Forenede Stater, 45229
- Cincinnati Children's Hospital Medical Center
-
Cincinnati, Ohio, Forenede Stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Forenede Stater, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Forenede Stater, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Forenede Stater, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Forenede Stater, 44109
- MetroHealth Medical Center
-
Columbus, Ohio, Forenede Stater, 43205
- Nationwide Children's Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Forenede Stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
- Mercy Hospital Oklahoma City
-
Tulsa, Oklahoma, Forenede Stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Baker City, Oregon, Forenede Stater, 97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend, Oregon, Forenede Stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forenede Stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forenede Stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Forenede Stater, 97420
- Bay Area Hospital
-
Newberg, Oregon, Forenede Stater, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Forenede Stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Forenede Stater, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Forenede Stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forenede Stater, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Forenede Stater, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Philadelphia, Pennsylvania, Forenede Stater, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- University of Pennsylvania/Abramson Cancer Center
-
-
South Carolina
-
Boiling Springs, South Carolina, Forenede Stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Columbia, South Carolina, Forenede Stater, 29203
- Prisma Health Richland Hospital
-
Easley, South Carolina, Forenede Stater, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forenede Stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forenede Stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Forenede Stater, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Forenede Stater, 29605
- BI-LO Charities Children's Cancer Center
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Forenede Stater, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Forenede Stater, 29672
- Prisma Health Cancer Institute - Seneca
-
-
Tennessee
-
Chattanooga, Tennessee, Forenede Stater, 37404
- Memorial Hospital
-
Hixson, Tennessee, Forenede Stater, 37343
- Pulmonary Medicine Center of Chattanooga-Hixson
-
Knoxville, Tennessee, Forenede Stater, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Forenede Stater, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Forenede Stater, 37203
- The Children's Hospital at TriStar Centennial
-
Ooltewah, Tennessee, Forenede Stater, 37363
- Memorial GYN Plus
-
-
Texas
-
Austin, Texas, Forenede Stater, 78723
- Dell Children's Medical Center of Central Texas
-
Bryan, Texas, Forenede Stater, 77802
- Saint Joseph Regional Cancer Center
-
Corpus Christi, Texas, Forenede Stater, 78411
- Driscoll Children's Hospital
-
El Paso, Texas, Forenede Stater, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Forenede Stater, 76104
- Cook Children's Medical Center
-
San Antonio, Texas, Forenede Stater, 78207
- Children's Hospital of San Antonio
-
-
Utah
-
American Fork, Utah, Forenede Stater, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Forenede Stater, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Forenede Stater, 84321
- Logan Regional Hospital
-
Murray, Utah, Forenede Stater, 84107
- Intermountain Medical Center
-
Ogden, Utah, Forenede Stater, 84403
- McKay-Dee Hospital Center
-
Riverton, Utah, Forenede Stater, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Forenede Stater, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, Forenede Stater, 84143
- LDS Hospital
-
St. George, Utah, Forenede Stater, 84770
- Saint George Regional Medical Center
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Aberdeen, Washington, Forenede Stater, 98520
- Providence Regional Cancer System-Aberdeen
-
Auburn, Washington, Forenede Stater, 98001
- MultiCare Auburn Medical Center
-
Bellevue, Washington, Forenede Stater, 98004
- Overlake Medical Center
-
Bellingham, Washington, Forenede Stater, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Forenede Stater, 98166
- Saint Anne Hospital
-
Centralia, Washington, Forenede Stater, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Forenede Stater, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Forenede Stater, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Forenede Stater, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Forenede Stater, 98003
- Saint Francis Hospital
-
Gig Harbor, Washington, Forenede Stater, 98335
- MultiCare Gig Harbor Medical Park
-
Issaquah, Washington, Forenede Stater, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Forenede Stater, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Forenede Stater, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Forenede Stater, 98499
- Saint Clare Hospital
-
Longview, Washington, Forenede Stater, 98632
- PeaceHealth Saint John Medical Center
-
Port Townsend, Washington, Forenede Stater, 98368
- Jefferson Healthcare
-
Poulsbo, Washington, Forenede Stater, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Puyallup, Washington, Forenede Stater, 98372
- MultiCare Good Samaritan Hospital
-
Renton, Washington, Forenede Stater, 98055
- Valley Medical Center
-
Seattle, Washington, Forenede Stater, 98105
- Seattle Children's Hospital
-
Seattle, Washington, Forenede Stater, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Forenede Stater, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Forenede Stater, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Forenede Stater, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Forenede Stater, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Forenede Stater, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Forenede Stater, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Forenede Stater, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Spokane, Washington, Forenede Stater, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Forenede Stater, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
Spokane Valley, Washington, Forenede Stater, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Tacoma, Washington, Forenede Stater, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Forenede Stater, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Forenede Stater, 98431
- Madigan Army Medical Center
-
Tacoma, Washington, Forenede Stater, 98405
- MultiCare Tacoma General Hospital
-
Tacoma, Washington, Forenede Stater, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Forenede Stater, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Forenede Stater, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, Forenede Stater, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm, Washington, Forenede Stater, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Bridgeport, West Virginia, Forenede Stater, 26330
- United Hospital Center
-
Martinsburg, West Virginia, Forenede Stater, 25401
- WVUH-Berkely Medical Center
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Forenede Stater, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Ashland, Wisconsin, Forenede Stater, 54806
- Duluth Clinic Ashland
-
Ashland, Wisconsin, Forenede Stater, 54806
- Northwest Wisconsin Cancer Center
-
Burlington, Wisconsin, Forenede Stater, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls, Wisconsin, Forenede Stater, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Fond du Lac, Wisconsin, Forenede Stater, 54937
- Aurora Health Center-Fond du Lac
-
Germantown, Wisconsin, Forenede Stater, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Forenede Stater, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Forenede Stater, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Forenede Stater, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Gundersen Lutheran Medical Center
-
Ladysmith, Wisconsin, Forenede Stater, 54848
- Marshfield Medical Center - Ladysmith
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Forenede Stater, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forenede Stater, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Forenede Stater, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Forenede Stater, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Forenede Stater, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau, Wisconsin, Forenede Stater, 54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Forenede Stater, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forenede Stater, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne, Wyoming, Forenede Stater, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Forenede Stater, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Forenede Stater, 82801
- Welch Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
PHASE I (ARMS A, B, C, D, E, F, G, H, I, X, Y, Z)
-
Age >= 18 years
-
Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted
-
Patients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host disease
-
Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients in the nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumab
-
Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)
-
Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) performance status between 0-2
-
Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
-
Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient of childbearing potential and/or sexually active patients must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately
-
Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air
-
Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration
-
Absolute neutrophil count (ANC) >= 1500/mcL (1.5 x 10^9/L) (obtained within 2 weeks prior to registration)
-
Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (obtained within 2 weeks prior to registration)
-
Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)
-
Calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)
-
No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response
-
Patient must have no current or prior history of central nervous system (CNS) involvement
-
All prior therapy must have been completed at least 21 days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed
-
No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy
-
Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded
-
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed
- Replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to initiation of study treatment are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study
- Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
-
Patients must not have grade 2 or greater peripheral sensory neuropathy
-
Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
-
Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
-
Patients must not have a serious medical or psychiatric illness likely to interfere with study participation
-
Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration
-
Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment
-
Patients registering to Arms D, E, F, G, H, I, X, Y must not currently be smoking tobacco or other substances and must not have smoked within the past 6 months
-
RANDOMIZED PHASE II (ARMS K AND L): Age >= 12 years
- Pediatric patients will include any patients < 18 years of age
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplant (out of risk of reactivation of pulmonary graft versus host disease [GVHD])
-
RANDOMIZED PHASE II (ARMS K AND L): Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients may not have received prior ipilimumab
-
RANDOMIZED PHASE II (ARMS K AND L): Patients may not have received other prior activating immunotherapies (i.e. checkpoint inhibitor therapies); for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)
-
RANDOMIZED PHASE II (ARMS K AND L): Adult patient (>= 18 years of age) ECOG-ACRIN performance status between 0-2
- Pediatric patients (16-17 years of age) must have a Karnofsky performance level >= 50%
- Pediatric patients (12-15 years of age) must have a Lansky performance level >= 50
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
-
RANDOMIZED PHASE II (ARMS K AND L): Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
RANDOMIZED PHASE II (ARMS K AND L): Patient of childbearing potential and/or sexually active patient must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately
-
RANDOMIZED PHASE II (ARMS K AND L): Patients with impaired decision-making capacity are eligible with legally authorized representative
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration
-
RANDOMIZED PHASE II (ARMS K AND L): ANC >= 1500/mcL (1.5 x 0^9/L) (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): AST/ALT =< 2.5 x upper limit of normal (ULN) for age (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Adult patients (>= 18 years old) must have a calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Pediatric patients (< 18 years old) must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine based on age/sex as follows:
-
Age: maximum serum creatinine (mg/dL)
- < 13 years: male (1.2), female (1.2)
- 13 to < 16 years: male (1.5), female (1.4)
- >= 16 years: male (1.7), female (1.4)
-
-
RANDOMIZED PHASE II (ARMS K AND L): No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response
-
RANDOMIZED PHASE II (ARMS K AND L): Patient must have no current or prior history of CNS involvement
-
RANDOMIZED PHASE II (ARMS K AND L): All prior therapy must have been completed at least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C); no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed
-
RANDOMIZED PHASE II (ARMS K AND L): No history of Steven's Johnson's syndrome, TENs syndrome, or motor neuropathy
-
RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:
- Long term survival expected were it not for the cHL
- HIV viral loads undetectable by standard clinical HIV testing
- Willing to adhere to effective combination antiretroviral therapy
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have autoimmune disorders, prior solid organ transplant, or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of steroid medication for at least 2 weeks prior to initiation of therapy are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have grade 2 or greater peripheral sensory neuropathy
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have NYHA class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a serious medical or psychiatric illness likely to interfere with study participation
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration
-
RANDOMIZED PHASE II (ARMS K AND L): Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not currently be smoking tobacco or other agents; vaping is not allowed
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a history of or evidence of cardiovascular risks including any of the following:
- QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec at baseline
- History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within the past 24 weeks prior to registration
- History prior to registration or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
- Left ventricular ejection fraction (LVEF) =< lower limit of normal on cardiac echocardiogram (echo) or multigated acquisition scan (MUGA)
- Intra-cardiac defibrillator
- History of abnormal cardiac valve morphology (>= grade 2) documented by ECHO; (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study
- History or evidence of current clinically significant uncontrolled cardiac arrhythmias; clarification: subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible
- Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Phase I Arm I (brentuximab vedotin, ipilimumab)
Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo biopsy
Andre navne:
Undergo collection of blood
Andre navne:
Given IV
Andre navne:
Undergo PET
Andre navne:
|
|
Eksperimentel: Phase I Arm II (brentuximab vedotin, nivolumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Undergo CT
Andre navne:
Undergo biopsy
Andre navne:
Undergo collection of blood
Andre navne:
Given IV
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
|
|
Eksperimentel: Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo biopsy
Andre navne:
Undergo collection of blood
Andre navne:
Given IV
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
|
|
Eksperimentel: Phase II Arm I (brentuximab vedotin, nivolumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Undergo CT
Andre navne:
Undergo biopsy
Andre navne:
Undergo collection of blood
Andre navne:
Given IV
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
|
|
Eksperimentel: Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo biopsy
Andre navne:
Undergo collection of blood
Andre navne:
Given IV
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum tolerated dose (MTD) of each combination (Phase I)
Tidsramme: 21 days
|
MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity, will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Upon completion of the trial, frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE version 4.0 terminology. Exact 95% confidence intervals (CI) around the toxicity proportions will be calculated. |
21 days
|
|
CR rate (Phase II)
Tidsramme: Up to 10 years
|
The analysis of CR between two arms will be performed using exact Cochran-Mantel-Haenszel (CMH) test stratifying on prior brentuximab vedotin (BV) (yes versus [vs.] no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. |
Up to 10 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete response (CR) rate (Phase I)
Tidsramme: Up to 3 years
|
Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI. |
Up to 3 years
|
|
Partial response (PR) rate (Phase I)
Tidsramme: Up to 3 years
|
Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI. |
Up to 3 years
|
|
Overall response rate (ORR) rate (Phase I)
Tidsramme: Up to 3 years
|
Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI. |
Up to 3 years
|
|
Duration of response (DOR) (Phase I)
Tidsramme: From the documented beginning of response up to 3 years
|
DOR will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. Descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy. |
From the documented beginning of response up to 3 years
|
|
Overall survival (OS) (Phase I)
Tidsramme: From the date of study entry up to 3 years
|
OS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. |
From the date of study entry up to 3 years
|
|
Progression-free survival (PFS) (Phase I)
Tidsramme: From entry onto study up to 3 years
|
PFS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. |
From entry onto study up to 3 years
|
|
ORR (Phase II)
Tidsramme: Up to 10 years
|
Assessed using Revised Response (Cheson) and Deauville criteria. The analysis of ORR between two arms will be performed using the CMH test stratifying on prior BV (yes vs. no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. |
Up to 10 years
|
|
PFS (or modified PFS) (Phase II)
Tidsramme: From randomization up to 10 years
|
PFS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals. |
From randomization up to 10 years
|
|
OS (Phase II)
Tidsramme: From randomization up to 10 years
|
OS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals. |
From randomization up to 10 years
|
|
DOR (Phase II)
Tidsramme: From the documented beginning of response up to 10 years
|
DOR, will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 90% confidence intervals. The DOR achieved with the most recent prior systemic therapy will be collected on the case report forms, and descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy. |
From the documented beginning of response up to 10 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Effekter af kombinationer på systemisk immunitet (fase I og II)
Tidsramme: Baseline til op til 6 uger efter afslutning af undersøgelsesbehandling
|
Baseline til op til 6 uger efter afslutning af undersøgelsesbehandling
|
|
|
Change in the percentage of activated T cells and natural killer cells (Phase I and II)
Tidsramme: Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)
|
These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year versus (vs.) those who are event-free at one year will be evaluated. |
Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)
|
|
Change in the percentages of activated T cells and natural killer cells (Phase I and II)
Tidsramme: Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)
|
These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using the Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated. |
Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)
|
|
Pre- and post-treatment levels of cytokines and T cell specific biomarkers (Phase I and II)
Tidsramme: Baseline to up to 6 weeks after completion of study treatment
|
Pre- and post-treatment levels of these markers will be compared using the Wilcoxon signed-rank test with two-sided type I error of 0.1. Marker levels between patients who fail at 1-year vs. patients who are event-free at 1-year will be evaluated. Given limited data, the analyses of PD-1, co-expression of Tim-3 with PD-1, ICOS, sCD30, galectin-1 and the peripheral blood absolute lymphocyte to monocyte ratio will be mainly exploratory and will be summarized descriptively at the time-points described above. The association with PFS will be explored. |
Baseline to up to 6 weeks after completion of study treatment
|
|
Differentially expressed genes between two groups (patients who fail at 1-year vs. patients who are event-free at 1-year or responders vs. non-responders) (Phase I and II)
Tidsramme: 1 year
|
Assessed using gene expression profiling (GEP). Differentially expressed genes will be identified using a rank-based method developed by Dr. Hong (RankProd, R package, Bioconductor Project) with multiple comparison adjustment using a false discovery rate approach. A two-way unsupervised hierarchical clustering analysis will be applied to both the genes and the samples to illustrate whether GEP can separate two groups or is associated with other clinical factors. The genes ranked as most significant will be assessed by gene ontology and pathway analysis for their potential functions in lymphoma biology and treatment failure. |
1 year
|
|
Microbiome analysis (Phase I and II)
Tidsramme: Completion of study treatment
|
Will compare the gut microbiome between Hodgkin lymphoma (HL) patients and healthy controls with respect to global diversity, taxonomic abundance, and bacterial functional pathways. The relative abundance of each taxon (phyla to genera) and functional pathways among different groups will be statistically compared in univariate analysis using t-test (or Wilcoxon test) and in multivariate analysis using logistic regression. Global diversity tests and multivariate analysis for taxonomic abundance and functional pathways will be adjusted for potential confounders (age, sex, race, and body mass index) in the comparisons of HL patients and controls, and further adjusted for stage and grade when examining the clinical response among HL patients. |
Completion of study treatment
|
|
Absolute maximum standard uptake value (SUVmax) (Phase II)
Tidsramme: Up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, event free survival (EFS), OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (Kaplan-Meier [KM] curve and log-rank testing). |
Up to cycle 10
|
|
Metabolic whole body tumor volume (MTV) and tumor lesion glycolysis (TLG)
Tidsramme: Up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Up to cycle 10
|
|
Percent change in SUVmax, MTV and TLG between baseline and during therapy
Tidsramme: Baseline up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Baseline up to cycle 10
|
|
Percent change in size (sum of perpendicular diameters [SPD]) on computed tomography (CT)
Tidsramme: Baseline up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Baseline up to cycle 10
|
|
Absolute CT tumor volumes
Tidsramme: Up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Up to cycle 10
|
|
Percent change in CT size (SPD) and in CT tumor volume between baseline and during therapy
Tidsramme: Baseline up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Baseline up to cycle 10
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Catherine S Diefenbach, ECOG-ACRIN Cancer Research Group
Publikationer og nyttige links
Generelle publikationer
- Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0.
- Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.
- Gonzalez-Kozlova E, Huang HH, Jagede OA, Tuballes K, Del Valle DM, Kelly G, Patel M, Xie H, Harris J, Argueta K, Nie K, Barcessat V, Moravec R, Altreuter J, Duose DY, Kahl BS, Ansell SM, Yu J, Cerami E, Lindsay JR, Wistuba II, Kim-Schulze S, Diefenbach CS, Gnjatic S. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. Cancer Res Commun. 2024 Jul 1;4(7):1726-1737. doi: 10.1158/2767-9764.CRC-24-0252.
- Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities. Oncoimmunology. 2024 May 9;13(1):2351255. doi: 10.1080/2162402X.2024.2351255. eCollection 2024.
- Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026 Apr 30;147(18):2041-2052. doi: 10.1182/blood.2025029546.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Peptider
- Aminosyrer, peptider og proteiner
- Oligopeptider
- Proteiner
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Biologiske faktorer
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Receptorer, celleoverflade
- Membranproteiner
- Antigener
- Antigener, overflade
- Biomarkører
- Receptorer, immunologisk
- Antigener, differentiering, T-lymfocyt
- Antigener, differentiering
- Immune kontrolpunktsproteiner
- Costimulerende og inhiberende T-celle-receptorer
- Nivolumab
- Ipilimumab
- Brentuximab Vedotin
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- CTLA-4-antigen
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2013-01275
- U10CA180820 (U.S. NIH-bevilling/kontrakt)
- U24CA196172 (U.S. NIH-bevilling/kontrakt)
- NCI-2013-01275 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- E4412 (Anden identifikator: CTEP)
- S14-00011
- E4412
- E4412 (Anden identifikator: ECOG-ACRIN Cancer Research Group)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .